Manuel B Graeber Selected Research

Central Nervous System Tuberculosis

2/2007	IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis.
1/2007	Monocyte-astrocyte networks regulate matrix metalloproteinase gene expression and secretion in central nervous system tuberculosis in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuel B Graeber Research Topics

Disease

7	Glioma (Gliomas) 02/2024 - 11/2002
7	Parkinson Disease (Parkinson's Disease) 01/2019 - 06/2005
6	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 10/2008
5	Inflammation (Inflammations) 12/2021 - 03/2004
3	Neoplasms (Cancer) 02/2024 - 01/2007
3	Neuroinflammatory Diseases 12/2021 - 11/2014
3	Glioblastoma (Glioblastoma Multiforme) 02/2021 - 04/2019
2	Cognitive Dysfunction 01/2019 - 01/2014
2	Dementia (Dementias) 01/2019 - 02/2008
2	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2018 - 07/2015
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 01/2017
2	Brain Neoplasms (Brain Tumor) 09/2016 - 11/2002
2	Central Nervous System Tuberculosis 02/2007 - 01/2007
1	Confusion (Bewilderment) 12/2021
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2021
1	Central Nervous System Neoplasms 09/2016
1	Fibrosis (Cirrhosis) 12/2014
1	Synucleinopathies 11/2006
1	Multiple System Atrophy 11/2006
1	Disease Progression 06/2005
1	Wounds and Injuries (Trauma) 03/2004
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/2004
1	Parkinsonian Disorders (Parkinsonism) 08/2003
1	Central Nervous System Infections (Central Nervous System Infection) 11/2002

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 02/2024 - 01/2007
4	CytokinesIBA 12/2022 - 11/2002
4	alpha-SynucleinIBA 01/2019 - 06/2005
3	Biomarkers (Surrogate Marker)IBA 04/2019 - 04/2009
2	Amyloid beta-PeptidesIBA 10/2008 - 02/2008
1	PENTAIBA 12/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 02/2021
1	Hematoxylin (Haematoxylon)IBA 02/2021
1	LipidsIBA 01/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021
1	Cholinergic Agents (Cholinergics)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	LigandsIBA 01/2017
1	AntigensIBA 09/2016
1	DNA-Binding Proteins (DNA Binding Protein)IBA 07/2015
1	AmmoniaIBA 12/2014
1	Glutathione (Reduced Glutathione)IBA 01/2014
1	Protons (Proton)IBA 01/2014
1	AntioxidantsIBA 01/2014
1	Presenilin-1IBA 02/2013
1	Therapeutic UsesIBA 08/2012
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2010
1	neuronal pentraxinIBA 04/2008
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 02/2007
1	Matrix Metalloproteinases (MMPs)IBA 01/2007
1	alfacalcidolIBA 11/2006
1	Histocompatibility Antigens Class IIIBA 06/2005
1	Indicators and Reagents (Reagents)IBA 06/2005
1	NeurotoxinsIBA 03/2004
1	Antipsychotic Agents (Antipsychotics)IBA 08/2003
1	Interferon-gamma (Interferon, gamma)IBA 11/2002
1	PlasticsIBA 11/2002

Therapy/Procedure

1	Therapeutics 01/2020
1	Axotomy 03/2004